Swedish TV4: Watch how genomics and machine learning are replacing animal testing in chemical safety

SenzaGen joined Lund University researchers on Swedish TV4 to show how genomics- and machine learning-based methods are transforming the field — delivering faster, more accurate, and human-relevant safety assessment.

See how these approaches can protect human health, meet evolving regulatory demands, and open new opportunities in a market driven by scientific innovation and the global shift away from animal testing.

▶️ Watch interview 

SenzaGen’s Newsletter Q1 2026

Click image to view the Newsletter in browser.

 

Text version:

SenzaGen Newsletter Q1, 2026

SOT 2026: Advancing NAMs for skin and respiratory sensitization testing

We had a fantastic time at this year’s SOT meeting in San Diego, connecting with peers, exploring new ideas, and sharing the latest GARD® data on skin and respiratory sensitization from our industry collaborations. Thank you to all our collaborative partners for the outstanding teamwork!

Bayer | Coty | ExxonMobil | GDIT | Haleon | J&J MedTech | Merck

GARD for assessing biopesticides and complex mixtures

Dr Andy Forreryd and Dr Tim Lindberg of SenzaGen presented at SOT symposium sessions, demonstrating how GARD® supports sensitization assessment of biopesticides and complex mixtures.

Respiratory sensitization, protein allergy and medical devices

At SenzaGen’s hosted session, guest speakers from Merck, GDIT, and J&J MedTech shared new GARD® data on respiratory sensitization and ISO 10993-10 compliance for medical devices.

New scientific publication: Quantitative risk assessment of fragrance materials using NAMs

The collaborative work within the International Dialogue for the Evaluation of Allergens (IDEA) has been recently published in Regulatory Toxicology and Pharmacology, presenting new peer-reviewed evidence on the application of New Approach Methodologies (NAMs) in quantitative risk assessment (QRA) of fragrance materials.

The study demonstrates that SenzaGen’s single-assay method GARD®skin Dose-Response, alongside the multiple-assay approaches, delivers PoDs that well align with established human and animal reference potency data, within the expected biological variability.

Read the full article

Establishing safe dose levels for cosmetic ingredients

We are pleased to see another leading global cosmetics company adopt GARD®skin Dose-Response to assess safe use levels of ingredients with potential skin-sensitizing properties. Powered by genomics and machine learning, the assay can be used as a standalone method to support robust, science-driven product development.

Explore 3 typical use scenarios

Upcoming events

🌎 Conference: ITCASS and ERGECD meeting | Strasbourg, France | April 15-17
🎧 Webinar: Advancing NAMs for respiratory sensitization testing-SOT Recap | Apr 22
🌎 Conference: ESTIV Congress | Maastricht, the Netherlands | June 29-July 2